Compare ABUS & AWF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABUS | AWF |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.8M | 868.3M |
| IPO Year | 2008 | N/A |
| Metric | ABUS | AWF |
|---|---|---|
| Price | $4.56 | $10.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 601.6K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.57% |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $14,083,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $239.71 | N/A |
| P/E Ratio | $5.28 | ★ N/A |
| Revenue Growth | ★ 128.21 | N/A |
| 52 Week Low | $3.04 | $9.85 |
| 52 Week High | $5.10 | $11.43 |
| Indicator | ABUS | AWF |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 54.65 |
| Support Level | $4.16 | $9.98 |
| Resistance Level | $4.60 | $10.58 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 67.81 | 92.50 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.